Log in

NASDAQ:PDLIPDL BioPharma Stock Price, Forecast & News

$2.66
-0.07 (-2.56 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.63
Now: $2.66
$2.76
50-Day Range
$2.53
MA: $3.18
$3.74
52-Week Range
$2.06
Now: $2.66
$3.89
Volume508,034 shs
Average Volume1.80 million shs
Market Capitalization$328.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures, markets, and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Read More
PDL BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.76 million
Cash Flow$0.43 per share
Book Value$5.20 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees105
Market Cap$328.75 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.


PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

How has PDL BioPharma's stock been impacted by COVID-19 (Coronavirus)?

PDL BioPharma's stock was trading at $3.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PDLI shares have decreased by 13.4% and is now trading at $2.66. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PDL BioPharma.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for PDL BioPharma.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings data on Wednesday, March, 11th. The biotechnology company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.53. The biotechnology company earned ($5.80) million during the quarter. During the same quarter in the previous year, the firm earned $0.11 EPS. View PDL BioPharma's earnings history.

How will PDL BioPharma's stock buyback program work?

PDL BioPharma declared that its board has initiated a stock buyback program on Monday, September 24th 2018, which allows the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 27.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.

What price target have analysts set for PDLI?

1 brokers have issued 12-month target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for PDL BioPharma.

Has PDL BioPharma been receiving favorable news coverage?

News headlines about PDLI stock have trended very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PDL BioPharma earned a news impact score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutPDL BioPharma.

Are investors shorting PDL BioPharma?

PDL BioPharma saw a decline in short interest in March. As of March 13th, there was short interest totaling 6,920,800 shares, a decline of 10.8% from the February 27th total of 7,760,000 shares. Based on an average trading volume of 2,074,900 shares, the days-to-cover ratio is currently 3.3 days. Approximately 6.3% of the shares of the stock are sold short. View PDL BioPharma's Current Options Chain.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), NovaBay Pharmaceuticals (NBY) and Cara Therapeutics (CARA).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the following people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.66.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $328.75 million and generates $54.76 million in revenue each year. The biotechnology company earns $-70,410,000.00 in net income (profit) each year or $0.28 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe. View additional information about PDL BioPharma.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is http://www.pdl.com/.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel